Efficacy of Sorafenib

Sorafenib (Sorafenib) is a cancer drug that contains the active substance Sorafenib and is used to treat patients with hepatocellular carcinoma, advanced renal cell carcinoma in whom anticancer treatment with interferon alpha or interleukin 2 has failed or cannot be used, and differentiated thyroid cancer that has developed or spread locally or to other parts of the body and has not responded to radioactive iodine therapy. Because the number of patients with these diseases is so small, these diseases are considered "rare," and sorafenib was designated a "rare" orphan drug.

Sorafenib was more effective than placebo at prolonging the time patients survived, or the time they lived without their disease getting worse. In studies of hepatocellular carcinoma, patients taking sorafenib lived an average of 10.7 months. In studies of renal cell carcinoma, patients who took sorafenib lived an average of 19.3 months, and those who took sorafenib lived longer without their disease getting worse (167 days, about five and a half months). In studies of differentiated thyroid cancer, patients taking sorafenib lived an average of 10.8 months without their disease worsening.

SorafenibThe original drug has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. SpecificationsThe price of 0.2g*60 tablets may be around RMB 1,200. The original drug of sorafenib has also been launched overseas, and there are also sorafenib generic drugs produced in other countries. The specifications produced by Bangladesh Pharmaceutical FactoryThe price of 0.2g*60 tablets is around 450 yuan (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of the original drug are basically the same as those of the generic drugs. For specific prices and drug details, please consult the medical consultant of Yaode.